Skip Navigation



Brain Advance Access published online on March 2, 2006

Brain, doi:10.1093/brain/awl047
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
129/5/1281    most recent
awl047v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Thomas, P.
Right arrow Articles by Genton, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Thomas, P.
Right arrow Articles by Genton, P.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author (2006). Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org
Received October 31, 2005
Revised January 20, 2006
Accepted January 27, 2006

Article

Absence and myoclonic status epilepticus precipitated by antiepileptic drugs in idiopathic generalized epilepsy

Pierre Thomas 1 *, Luc Valton 2, and Pierre Genton 3

1 Unité Fonctionnelle EEG-Epileptologie, Service de Neurologie, Hôpital Pasteur, Nice, France
2 Unité d'Epileptologie, Service de Neurologie, Hôpital Rangueil, Toulouse, France
3 Centre Saint Paul-Hôpital Henri Gastaut, Marseilles, France

* To whom correspondence should be addressed.
Pierre Thomas, E-mail: piertho{at}wanadoo.fr


   Abstract

Aggravation of idiopathic generalized epilepsy (IGE) syndromes by inappropriate antiepileptic drugs (AEDs) is increasingly recognized as a serious and common problem. Precipitation of status epilepticus (SE) by inappropriate medication has rarely been reported. We retrospectively studied all adult patients with IGE taking at least one potentially aggravating AED, who developed video-EEG documented SE over 8 years, and whose long-term outcome was favourable after adjustment of medication. We identified 14 patients (seven male patients) aged 15-46 years with a mean duration of epilepsy of 16.4 years. Video-EEG demonstrated typical absence SE (ASE) in five, atypical ASE in five, atypical myoclonic SE (MSE) in three and typical MSE in one. Epilepsy had been misclassified as cryptogenic partial in eight cases and cryptogenic generalized in four. The correct diagnosis proved to be juvenile absence epilepsy (JAE) in six patients, juvenile myoclonic epilepsy (JME) in four, epilepsy with grand mal on awakening (EGMA) in two and childhood absence epilepsy (CAE) in two. All patients had been treated with carbamazepine (CBZ) and had experienced seizure aggravation or new seizure types before referral. Seven patients had polytherapy with phenytoin (PHT), vigabatrin (VGB) or gabapentin (GBP). Potential precipitating factors included dose increase of CBZ or of CBZ and PHT; initiation of CBZ, VGB or GBP; and decrease of phenobarbital. Withdrawal of the aggravating agents and adjustment of medication resulted in full seizure control. This series shows that severe pharmacodynamic aggravation of seizures in IGE may result in ASE or MSE, often with atypical features.

Keywords: status epilepticus; adverse effects; antiepileptic drugs; epilepsy prognosis.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Arch NeurolHome page
J. J. Palop and L. Mucke
Epilepsy and Cognitive Impairments in Alzheimer Disease
Arch Neurol, April 1, 2009; 66(4): 435 - 440.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.